Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like CagriSema and Zenagamtide, but lacks immediate catalysts. Despite a strong recent stock performance and a valuation that appears cheap compared to peers, concerns remain over market share losses and expectations of further revenue and profit declines. Analysts currently maintain a 'hold' rating on the stock, reflecting cautious optimism amid these mixed factors.
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Novo Resources has filed a technical report confirming the mineral resource estimate for the Leven Star Reef gold project in Victoria, Australia, matching earlier estimates. Additionally, drilling at the Wyloo Polymetallic Project in Western Australi...
Novo Resources Corp. has filed a technical report on the Mineral Resource Estimate for the Leven Star Reef at its 100% owned Belltopper Gold Project in Victoria, Australia. The report, prepared by qualified experts, confirms the previously announced ...
Novo Resources Corp. has released an updated corporate presentation detailing its strategic priorities, recent exploration results, and project advancements. The presentation provides investors with insights into the company's growth strategy and its...
